What this study is
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.
Study details
- Official title
- Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study
- Sponsor
- Massachusetts General Hospital
- Conditions
- Heart Failure With Normal Ejection Fraction · Heart Failure With Reduced Ejection Fraction · Heart Failure, Right Sided · Heart Failure With Mid Range Ejection Fraction · Cardiovascular Risk Factor
- Enrolling
- 3,000 people
- Starts
- 2016-04-07
- Est. completion
- 2028-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- 18 years and older
- History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF:; NT-proBNP > 125 pg/mL; BNP > 35 pg/mL; Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI <2.8 L/min/m2; LVEDP ≥ 15 mmHg; Radiographic evidence of pulmonary edema; Improvement in symptoms with diuretic initiation of increase; CPET evidence of cardiac etiology of symptoms HFpEF: LVEF ≥ 50% HFrEF: LVEF <50%
You can't join if
- End stage renal disease on dialysis
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openMassachusetts General Hospital
Boston, Massachusetts, United States
- Heather Jameson, PhD · Contact
- Hanna Gaggin, MD, MPH · Principal investigator
Recruiting
Study team
Sponsor
Massachusetts General Hospital
Study ID 2016P000339
Principal investigator
Hanna Gaggin, MD, MPH
Massachusetts General Hospital
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.